Efgartigimod for worsening myasthenia gravis in hospital
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have generalized myasthenia gravis with a positive blood test for acetylcholine receptor antibodies.
- Your MG symptoms are severe enough to need a hospital stay, such as trouble breathing, swallowing, or speaking.
- You are able to join the study within 24 hours of being admitted to the hospital.
- You have not had certain other treatments recently, like IVIG (intravenous immunoglobulin) in the last 2 weeks, or plasma exchange or efgartigimod in the last 4 weeks.
- You are not currently pregnant or breastfeeding, and you are not on certain other MG medications like ravulizumab or eculizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod for people with myasthenia gravis who are experiencing a sudden, severe worsening of symptoms (crisis). The drug may help reduce the need for a breathing tube or speed up recovery.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
Hear when a new Myasthenia Gravis Crisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.